Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A H Thompson

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Organic Letters|June 26, 2023
Synthetic Analogs of the Sponge Sesterterpenoid Alotaketal C are Potent Inhibitors of SARS-CoV-2 Omicron BA.1 and BA.5 Infections of Human Lung CellsPolina Blagojevic, Jimena Perez-Vargas, Kunzhong Jian, et al.
Antiviral Research|March 28, 2024
Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antiviralsJimena Pérez-Vargas, Gabriel Lemieux, Connor A H Thompson, et al.
Emerging Microbes & Infections|March 23, 2023
Berbamine suppresses intestinal SARS-CoV-2 infection via a BNIP3-dependent autophagy blockadeAlexandra P M Cloherty, Anusca G Rader, Kharishma S Patel, et al.
AIDS (London, England)|November 18, 2022
Dolutegravir-containing HIV therapy reversibly alters mitochondrial health and morphology in cultured human fibroblasts and peripheral blood mononuclear cellsAbhinav Ajaykumar, Loïc C Caloren, Tetiana Povshedna, et al.
Journal of Medicinal Chemistry|March 31, 2025
From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 VariantsGabriel Lemieux, Jimena Pérez-Vargas, Antoine Désilets, et al.
Emerging Microbes & Infections|January 30, 2026
TMPRSS2 inhibitors with broad-spectrum efficacy against SARS-CoV-2 (JN.1) and influenza A (H1N1) viruses protect mice from influenza A infectionLianne Presley, Jimena Pérez-Vargas, Anaïs Saintigny, et al.
Nature|March 28, 2022
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeuticTirosh Shapira, I Abrrey Monreal, Sébastien P Dion, et al.
Emerging Microbes & Infections|August 9, 2023
A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariantsJimena Pérez-Vargas, Liam J Worrall, Andrea D Olmstead, et al.
Research Square|June 12, 2026
A reversible broad-spectrum antiviral targets the human V-ATPase VO domainJimena Pérez-Vargas, Diana Bautista-Sánchez, Rebecca A Oot, et al.
Antiviral Research|December 12, 2022
Discovery of lead natural products for developing pan-SARS-CoV-2 therapeuticsJimena Pérez-Vargas, Tirosh Shapira, Andrea D Olmstead, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Organic Letters|June 26, 2023
Synthetic Analogs of the Sponge Sesterterpenoid Alotaketal C are Potent Inhibitors of SARS-CoV-2 Omicron BA.1 and BA.5 Infections of Human Lung CellsPolina Blagojevic, Jimena Perez-Vargas, Kunzhong Jian, et al.
Antiviral Research|March 28, 2024
Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antiviralsJimena Pérez-Vargas, Gabriel Lemieux, Connor A H Thompson, et al.
Emerging Microbes & Infections|March 23, 2023
Berbamine suppresses intestinal SARS-CoV-2 infection via a BNIP3-dependent autophagy blockadeAlexandra P M Cloherty, Anusca G Rader, Kharishma S Patel, et al.
AIDS (London, England)|November 18, 2022
Dolutegravir-containing HIV therapy reversibly alters mitochondrial health and morphology in cultured human fibroblasts and peripheral blood mononuclear cellsAbhinav Ajaykumar, Loïc C Caloren, Tetiana Povshedna, et al.
Journal of Medicinal Chemistry|March 31, 2025
From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 VariantsGabriel Lemieux, Jimena Pérez-Vargas, Antoine Désilets, et al.
Emerging Microbes & Infections|January 30, 2026
TMPRSS2 inhibitors with broad-spectrum efficacy against SARS-CoV-2 (JN.1) and influenza A (H1N1) viruses protect mice from influenza A infectionLianne Presley, Jimena Pérez-Vargas, Anaïs Saintigny, et al.
Nature|March 28, 2022
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeuticTirosh Shapira, I Abrrey Monreal, Sébastien P Dion, et al.
Emerging Microbes & Infections|August 9, 2023
A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariantsJimena Pérez-Vargas, Liam J Worrall, Andrea D Olmstead, et al.
Research Square|June 12, 2026
A reversible broad-spectrum antiviral targets the human V-ATPase VO domainJimena Pérez-Vargas, Diana Bautista-Sánchez, Rebecca A Oot, et al.
Antiviral Research|December 12, 2022
Discovery of lead natural products for developing pan-SARS-CoV-2 therapeuticsJimena Pérez-Vargas, Tirosh Shapira, Andrea D Olmstead, et al.
Pageof 8